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Introduction: Advanced squamous cell carcinoma (SqCC) of the 
lung carries a poor prognosis, and new therapeutic targets are needed. 
Several studies have examined dasatinib in non–small cell lung can-
cer; these report not only significant toxicities, but also responses in 
patients found to harbor mutations in discoidin domain receptor tyro-
sine kinase 2 or BRAF. An open-label phase II trial with dasatinib 
was carried out to determine the response rates in patients with SqCC 
who had previously failed standard chemotherapy and to correlate 
responses with patient genotype.
Methods: Patients were treated with dasatinib 140 mg daily in 
28-day cycles. Patients were included if they had stage IIIb/IV SqCC, 
Eastern Cooperative Oncology Group performance status of 0 or 1, 
and for whom treatment with standard chemotherapy had failed.
Results: The study was halted after enrolling five patients, all of 
whom were discontinued from the trial because of excess toxicity 
of dasatinib administered at 140 mg/day. The patients were treated 
for 9, 14, 24, 40, and 42 days. Three of five patients (60%) experi-
enced grade 3 or more toxicities (dyspnea, fatigue, elevated level of 
aspartate transaminase, anorexia, nausea). Intolerable grade 2 pleural 
effusions were noted in two of five patients. Four of five patients died 
after 44, 52, 127, and 226 days; one patient remains alive at 279 days. 
No deaths were associated with the study drug.
Conclusions: Similar to other studies, this study too found that 
dasatinib administered at 140 mg/day for the treatment of advanced 
SqCC of the lung is associated with excess adverse events, so is 
not recommended in unselected patients. Further work to identify 
patients likely to benefit from dasatinib and to manage dasatinib-
related toxicities is needed.
Key Words: Squamous cell cancer, Dasatinib, Lung neoplasms, 
Discoidin receptor.
(J Thorac Oncol. 2013;8: 1434–1437)
Non–small cell lung cancer (NSCLC) accounts for 85% of all lung malignancies and carries a poor prognosis. 
Platinum-based chemotherapy remains the standard of care; 
however, the discovery of oncogenic drivers and effective tar-
geted therapeutics has resulted in significant survival improve-
ments in certain patient subsets, notably those carrying ALK 
or EGFR alterations.1,2 The majority of these oncogenic driv-
ers are found in lung adenocarcinoma. Squamous cell carci-
noma (SqCC) of the lung, 25% of all NSCLCs, rarely contains 
EGFR or ALK alterations,3 thus new therapeutic targets are 
needed.
Preclinical work has identified a number of somatic pro-
tein kinase mutations in SqCC,4,5 including discoidin domain 
receptor tyrosine kinase 2 (DDR2) mutations, a receptor 
tyrosine kinase mutated in 3% to 4% of SqCC samples,3,5 
and rare kinase-inactivating BRAF mutations.6,7 Dasatinib, 
an aminothiazole analogue and SRC family kinase inhibitor, 
is active against BCR-ABL, SRC, c-KIT, and PDGFβ,8 and 
is a potent in vitro inhibitor of DDR2.9 Dasatinib induces 
cell death in DDR2-mutated cancer cell lines in vitro and 
decreases DDR2-mutant SqCC tumor growth in vivo in 
xenograft models.5 Dasatinib is approved for the treatment 
of chronic-phase or resistant chronic myelogenous leukemia 
and Philadelphia chromosome–positive acute lymphoblastic 
leukemia.
Recent trials evaluated dasatinib as monotherapy10 or 
combined with the EGFR inhibitor erlotinib7,11 in NSCLC. 
One trial dosed dasatinib at 150 to 200 mg alone in divided 
doses; common toxicities were dyspnea (grade 2, 3%; grade 
3, 44%), pleural effusion (grade 2, 26%; grade 3, 18%), 
fatigue (grade 2, 21%; grade 3, 6%), and lymphopenia (grade 
2, 15%; grade 3, 3%); mild gastrointestinal intolerance was 
common.10 A second trial used dasatinib 50 to 70 mg twice 
daily or 140 mg daily, with erlotinib; toxicities included GI 
intolerance (71%–88%), pleural effusion (35%), fatigue 
(74%), anemia (53%), lymphopenia (65%), and acneiform 
rash.7 A third trial dosed dasatinib at 100 mg daily or 70 mg 
twice daily, with erlotinib; complications included pleural 
effusion with chest tube placement in four of 21 patients, 
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grade 3 fatigue in four of 21 patients, and moderate nausea, 
vomiting, and diarrhea.11
Nonetheless, several responders were described.6,7,10 
Two partial responders received 70 mg dasatinib twice daily 
and erlotinib 150 mg daily: one had adenocarcinoma with an 
activating EGFR mutation; the other was a 59-year-old female 
smoker with DDR2-mutated SqCC.5,7 This second patient had 
tumor shrinkage, but discontinued therapy at 14 months for 
progressive pleural effusions. Another study reported a partial 
response in one patient treated with dasatinib 100 mg twice 
daily, with remission of metastatic lung adenocarcinoma and 
a stable metabolically inactive lung nodule;10 the tumor har-
bored a kinase-inactivating BRAF mutation.6
On the basis of these findings,6,7,10 we carried out an 
open-label, phase II study of dasatinib, dosed at 140 mg daily 
in patients with advanced-stage lung SqCC. The primary out-
come was to determine the overall response rate; secondary 
outcomes included DDR2 mutation analysis, overall and pro-
gression-free survival, and toxicities associated with dasatinib 
therapy.
PATIENTS AND METHODS
Patient Selection
Patients were enrolled at the Dana-Farber/Harvard 
Cancer Center, beginning in September 2011. Eligible patients 
were 18 years or older with measurable stage IIIb/IV lung 
SqCC, histologically or cytologically confirmed, had failed 
standard first-line platinum-based chemotherapy. Patients 
were excluded if pregnant, breastfeeding, known to be HIV 
positive, had uncontrolled hypertension, chronic gastrointes-
tinal disease, heart block or significant arrhythmias, bleeding 
disorders or recent gastrointestinal bleeding, active infection, 
were incarcerated or detained, or had uncontrolled medical ill-
ness or another concurrent active malignancy. Eligible patients 
could not be taking CYP3A4 inhibitors, proton pump inhibi-
tors, H2 blockers, drugs associated with torsades de pointes, 
or be allergic to tyrosine kinase inhibitors. A QTc interval of 
less than 470 msec was required. Also, a period of at least 
4 weeks must have passed since the patient received chemo-
therapy or radiotherapy. Additional exclusion criteria included 
untreated or progressive brain metastases, supplemental oxy-
gen, and symptomatic pleural or pericardial effusions unless 
the patient was undergoing therapeutic thoracentesis as part 
of nonstudy care.
All patients provided informed consent before enroll-
ment. The study was approved by the Dana-Farber Cancer 
Institute Institutional Review Board and registered with 
ClinicalTrials.gov, study number NCT01491633.
Treatment Protocol
All patients were treated with dasatinib (Sprycel, 
Bristol-Myers Squibb-354825) at a dose of 140 mg orally, 
daily in 28-day cycles, the maximum tolerated once-daily 
dose reported in prior studies of dasatinib in lung cancer. In 
the setting of grade 3 to 4 adverse events, the trial drug would 
be held and later resumed at a lower dose of 100 mg daily. One 
dose de-escalation was allowed.
Study Endpoints and Design
The primary outcome was overall clinical response 
rate (complete response + partial response) by Response 
Evaluation Criteria in Solid Tumors 1.1 criteria12 at 8-week 
intervals. Secondary outcomes included outcomes among 
patients with DDR2 mutations; overall and progression-free 
survival, defined as time from study enrollment to death or 
disease progression, respectively; and dasatinib-associated 
toxicities. Patient samples were collected for molecular 
testing and DDR2 genotype analysis with expanded geno-
typing for patients with responses and no DDR2 muta-
tions. Forty patients were planned to enroll in the trial; a 
two-stage Green–Dahlberg13 design was planned to moni-
tor subjects for clinical response and enable early stopping 
for futility after 20 patients were assessed. The study had a 
94.2% power to detect a 30% or more response rate com-
pared with reponse in historical controls (2-sided α 0.041). 
Discontinuation criteria included patient withdrawal, pro-
gressive disease, excessive toxicity, pregnancy, and investi-
gator decision.
RESULTS
Six patients enrolled between November 22, 2011 and 
September 19, 2012. One withdrew before treatment, resulting 
in five evaluable patients (Table 1). All five patients stopped 
treatment early because of unacceptable toxicity and poor 
drug tolerability. All had stage IV SqCC; three were men. One 
patient had a limited smoking history (<1 cigarette per week 
between the age of 18 and 54 years); otherwise all had sig-
nificant smoking histories (40, 75, 100, and 120 pack-years). 
Patients were treated for 9, 14, 24, 40, and 42 days. Median 
TABLE 1.  Baseline Patient Characteristics
Variable N (%)
Age
  Median (range) 59 (55–78)
Sex
  Male 3 (60)
  Female 2 (40)
ECOG performance status
  0 2 (40)
  1 3 (60)
Stage IV disease 5 (100)
Prior chemotherapy regimens
  Median (range) 2 (2–6)
Prior therapy
  Carboplatin/paclitaxel 4 (80)
  Platinum/gemcitabine 2 (40)
  Docetaxel 2 (40)
  Vinorelbine 3 (60)
  Platinum/etoposide 1 (20)
  Erlotinib or cetuximab 2 (40)
Radiation therapy 5 (100)
ECOG, Eastern Cooperative Oncology Group.
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follow-up was 127 days; four of five patients died during this 
period, and the survivor has been followed for 343 days. The 
patient who withdrew lived for 252 days. DDR2 mutations 
were not identified in any subject on study.
Treatment Course and Response
No patients were evaluable for clinical response during 
the trial because none were treated for 8 weeks. Three patients 
did not complete the first treatment cycle. Patient 1 was hospi-
talized for grade 3 dyspnea and stopped the study drug on day 
15 of cycle 1; he withdrew from the study without receiving 
further treatment. Patient 2 developed a grade 2 pleural effu-
sion, requiring hospitalization on day 9 of cycle 1 and was dis-
continued from the study; no chest tube was required during 
the hospital stay. Patient 6 had a dose reduction of dasatinib 
to 100 mg daily for fatigue on day 15; this persisted and he 
withdrew from the study on day 24. This patient died from his 
malignancy 44 days after enrollment. Of the remaining two 
patients, patient 4 developed fatigue during cycle 2 and dis-
continued the study drug on day 42; and patient 5 developed a 
pleural effusion and hemoptysis during cycle 2 and discontin-
ued the study drug on day 40.
Although no patients reached the 8-week evaluation 
point, two patients had nonstudy imaging performed. Patient 1 
had stable disease on a nonstudy assessment at day 15. Patient 
5 had a nonstudy assessment showing disease progression on 
day 41, and subsequently responded to a cyclin-dependent 
kinase (CDK) inhibitor in a phase I trial.
Toxicities
Three patients experienced grade 3 or more treatment-
related toxicities. The most common treatment-related toxic-
ity was pleural effusion (n = 2, grade 2; Table 2). Grade 3 
toxicities included dyspnea, elevated level of aspartate trans-
aminase, anorexia, nausea, and fatigue (1 patient each). One 
patient died from progressive NSCLC within 30 days from the 
last dose of dasatinib, not felt to be related to the study drug.
DISCUSSION
Advanced SqCC of the lung has a poor prognosis, and 
requires new therapeutic targets. Preclinical research suggests 
dasatinib may be effective against specific subsets of patients, 
particularly in patients with DDR2 mutations or inactivat-
ing BRAF mutations.5–7,10 Three phase II trials have evaluated 
dasatinib dosed at 140 to 200 mg daily in NSCLC, with or 
without erlotinib. Although toxicity was common (Table 2), 
several patients had responses at these doses.
Dasatinib-related toxicity and poor tolerability were the 
major treatment-limiting complications in our study, similar 
to other phase II trials, and led to early study closure. This 
may relate to dosing; previously, dasatinib monotherapy at 
100 mg twice daily had higher rates of pleural effusion (36% 
TABLE 2.  Toxicities Encountered in Trials Using Dasatinib for Thoracic Malignancies
This Report
Haura  
et al.7
Johnson 
et al.10 Johnson et al.11 Miller et al.15 Dudek et al.14
Total patients (n) 5 34 34 21 43 43
Thoracic malignancy Squamous cell lung carcinoma NSCLC NSCLC Lung adenocarcinoma Small-cell carcinoma Malignant mesothelioma
Total daily dasatinib 
dose (mg)
140 100–140 150–200 100–140 140 100–140
Other agents None Erlotinib None Erlotinib (n = 12) None None
Median PFS (mo) Not calculated 2.7 1.36 0.5 (dasatinib) 1.36 2.1
Pleural effusion
  Grade 2 2 (40%) 6 (18%) 9 (26%) n/a n/a 9%
  Grade 3 0 0 6 (18%) 4 (19%) 5 (11%)
Dyspnea
  Grade 2 0 4 (12%) 1 (3%) n/a n/a 7.50%
  Grade 3 1 (20%) 1 (1%) 15 (44%) n/a n/a
Fatigue
  Grade 2 0 15 (44%) 7 (21%) n/a n/a 11%
  Grade 3 1 (20%) 0 2 (6%) 4 (19%) 6 (14%)
Anorexia
  Grade 2 0 11 (32%) 2 (6%) n/a n/a n/a
  Grade 3 1 (20%) 0 0 n/a 1 (2%) n/a
Diarrhea
  Grade 2 0 6 (18%) 2 (6%) n/a n/a n/a
  Grade 3 0 2 (6%) 0 n/a 1 (2%) n/a
Nausea
  Grade 2 0 8 (24%) 2 (6%) n/a n/a n/a
  Grade 3 1 (20%) 0 0 1 (4.8%) 2 (5%) n/a
NSCLC, non–small-cell lung cancer; PFS, progression-free survival; n/a, not available.
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versus 16%) and fatigue (41% versus 0%) compared with 
100 mg/50 mg dosing.10 However, dasatinib 70 mg twice daily 
compared with dasatinib 140 mg once daily, both with erlo-
tinib, did not seem to have increased adverse events, among a 
small cohort.7 It is unknown whether erlotinib mitigates some 
dasatinib toxicity. Additionally, our patient population was 
heavily pretreated, which may have contributed to the frequent 
toxicities that we describe. Poor drug tolerability and limited 
efficacy in unselected patients is also described in other tho-
racic malignancies, including mesothelioma and small-cell 
lung cancer (Table 2).14,15 Previous trials note improved toxic-
ity profiles among patients receiving lower initial doses,10,11,14 
suggesting that lower or twice-daily dasatinib dosing, ini-
tiating treatment at lower doses, or having a lower toxicity 
threshold for dose reductions, may yield more favorable drug 
tolerability among molecularly selected patients than seen in 
the current analysis.
We believe that the toxicity profile seen with dasatinib 
dosed at 140 mg daily in NSCLC patients thus far precludes 
its use in unselected patients with advanced lung SqCC; 
however, there may be a subset of patients responsive to 
the drug. Unfortunately, this trial was stopped before iden-
tifying any such subgroups, though trials (NCT01514864, 
NCT01744652) of dasatinib for lung cancer patients 
selected on the basis of DDR2 and BRAF mutations are 
ongoing and designed to test whether there may be benefit 
in individuals with these specific biomarkers. Future tri-
als examining the role of dasatinib in SqCC should con-
sider a highly selected patient cohort given the toxicities 
we describe.
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